Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.83
+3.6%
$0.59
$0.24
$2.53
$47.03M1.031.09 million shs856,571 shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$10.66
-2.5%
$11.94
$2.80
$8.97
$384.38M0.6337,931 shs1.66 million shs
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
$19.75
-1.4%
$18.12
$5.80
$20.96
$2.07B2.081.87 million shs1,189 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
-12.00%+0.74%+3.36%+108.03%-60.15%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%0.00%0.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-3.45%+6.43%+8.97%-37.76%-24.72%
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
+2.55%-1.72%+8.62%+8.62%+8.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.83
+3.6%
$0.59
$0.24
$2.53
$47.03M1.031.09 million shs856,571 shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$10.66
-2.5%
$11.94
$2.80
$8.97
$384.38M0.6337,931 shs1.66 million shs
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
$19.75
-1.4%
$18.12
$5.80
$20.96
$2.07B2.081.87 million shs1,189 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
-12.00%+0.74%+3.36%+108.03%-60.15%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%0.00%0.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-3.45%+6.43%+8.97%-37.76%-24.72%
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
+2.55%-1.72%+8.62%+8.62%+8.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
1.75
ReduceN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBTX, BCAB, GRCL, and TRIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
BioAtla, Inc. stock logo
BCAB
BioAtla
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
BioAtla, Inc. stock logo
BCAB
BioAtla
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/13/2025
BioAtla, Inc. stock logo
BCAB
BioAtla
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket OutperformMarket Perform
8/13/2025
BioAtla, Inc. stock logo
BCAB
BioAtla
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$11M4.43N/AN/A$0.25 per share3.32
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$60K12,415.83N/AN/A$2.95 per share3.47
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
$150K13,825.39N/AN/A$2.56 per share7.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$69.78M-$1.10N/AN/AN/AN/A-1,177.18%-137.51%11/6/2025 (Estimated)
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
-$59.35M$0.6231.86N/AN/AN/A-23.31%-18.66%N/A

Latest SBTX, BCAB, GRCL, and TRIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.31N/AN/AN/AN/AN/A
8/7/2025Q2 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.29-$0.31-$0.02-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
1.24
1.24
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.02
7.73
7.73
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
N/A
19.82
19.82
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
6058.72 million52.13 millionOptionable
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
31472.68 million52.33 millionOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
33105.00 million95.44 millionNo Data

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$0.83 +0.03 (+3.63%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.03 (+3.37%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Gracell Biotechnologies stock logo

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$10.66 -0.27 (-2.47%)
As of 10/14/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Defiance Trillion Dollar Club Index ETF stock logo

Defiance Trillion Dollar Club Index ETF NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.